Sarepta’s revenue outlook slashed as FDA scrutiny deepens over gene therapy risks

Analysts’ expectations for Sarepta Therapeutics (NASDAQ: SRPT) have deteriorated sharply after fresh regulatory scrutiny cast new doubts over the future of its flagship gene therapy, Elevidys. Consensus forecasts from Visible Alpha show revenue estimates for the Duchenne muscular dystrophy (DMD) treatment in 2025 have dropped more than 55%, from $2.1 billion in March to $928 million, based on current analyst expectations. Expectations for total company revenue have also been cut—from $3.2 billion to $2 billion, highlighting uncertainty around Sarepta’s longer-term growth prospects in the gene therapy market.

The revisions follow Sarepta’s decision to pause shipments of Elevidys earlier this week, at the request of the US FDA. The move comes amid mounting safety concerns, including three patient deaths. Two teenage boys died earlier this year from acute liver injury, a known risk of the therapy, and last week the company reported a third death involving a 51-year-old patient in a separate clinical trial.

Shares in Sarepta have fallen 29% over the past week and are down nearly 90% year-to-date.

Elevidys, the first gene therapy approved in the US for DMD, initially received clearance for boys aged four and under who could still walk. The FDA later extended the approval to include older, non-ambulatory patients—broadening its commercial potential. But recent events raise questions about the durability of that opportunity as the company grapples with heightened regulatory oversight and deepening clinical risks.